華東醫藥(000963.SZ):中美華東引進Kiniksa兩款自身免疫領域全球創新產品
格隆匯2月23日丨華東醫藥(000963.SZ)公佈,2022年2月22日,公司全資子公司中美華東與美國上市公司Kiniksa Pharmaceuticals, Ltd.(Nasdaq: KNSA)的全資子公司Kiniksa簽訂了產品獨家許可協議。
中美華東獲得Kiniksa兩款自身免疫領域的全球創新產品Arcalyst®及Mavrilimumab在中國、韓國、澳大利亞、新西蘭、印度等24個亞太國家和地區(不含日本)的獨家許可,包括開發、註冊及商業化權益。中美華東將向Kiniksa支付2200萬美元首付款,最高不超過6.4億美元的開發、註冊及銷售里程碑付款,以及分級兩位數的淨銷售額提成費。
該次引進Kiniksa的2款自身免疫產品除已有適應症外,還具備開發其它潛在自身免疫適應症的潛力,可與公司現有免疫產品形成互補,有望在研發、臨牀、銷售等方面形成強大的協同效應,有助於更好地整合資源,釋放公司研發和技術優勢,提升公司在免疫領域的核心競爭力。
目前,通過自主研發及外部合作的驅動模式,公司在免疫領域擁有十款產品,形成了豐富及差異化的管線佈局,產品適應症覆蓋皮膚科、風濕科、心血管、呼吸科、腎內科、移植外科等科室,是國內免疫領域科室覆蓋最全的醫藥公司之一。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.